Despite growing recognition of human glutaminyl cyclase (hQC) as a promising therapeutic target for Alzheimer’s disease (AD), research has primarily focused on synthetic inhibitors, while natural compounds with potentially safer and multitargeted effects remain largely unexplored. Here, QPCT is linked to early-onset autosomal dominant Alzheimer disease.